close
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Palvella Therapeutics, Inc. - Common Stock (NQ:PVLA)

175.92 +19.07 (+12.16%)
Delayed Quote Updated: 4:00 PM EST, Nov 6, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Palvella Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 Next >
News headline image
What Palvella Therapeutics (PVLA) Said on Its Q3 Earnings Call ↗
Palvella Therapeutics (NASDAQ:PVLA) is preparing for a potential U.S. launch of QTORIN rapamycin after the Food and Drug Administration accepted its application for the treatment of microcystic... 
Via MarketBeat
Topics Earnings
News headline image
Palvella (PVLA) Q3 2026 Earnings Call Transcript ↗
QTORIN rapamycin wins priority FDA review for a rare vascular disease. 
Via The Motley Fool
Topics Earnings
PALVELLA THERAPEUTICS INC (NASDAQ:PVLA) Narrows Q3 Loss Ahead of February 2027 PDUFA Decision ↗
Via Chartmill
News headline image
Palvella Therapeutics Reports Third Quarter 2026 Financial Results and Provides Corporate Update
From Palvella Therapeutics Inc.
Via GlobeNewswire
News headline image
Palvella Therapeutics to Participate in the Stifel 2026 Healthcare Conference
From Palvella Therapeutics Inc.
Via GlobeNewswire
News headline image
Palvella Therapeutics to Host Third Quarter 2026 Financial Results and Corporate Update Conference Call on November 5, 2026
From Palvella Therapeutics Inc.
Via GlobeNewswire
News headline image
Palvella Announces FDA Acceptance and Priority Review of QTORIN™ Rapamycin NDA; February 28, 2027 PDUFA Target Action Date Set
From Palvella Therapeutics Inc.
Via GlobeNewswire
News headline image
Palvella Therapeutics Eyes QTORIN Launch as Rare-Disease Pipeline Expands ↗
Palvella Therapeutics (NASDAQ:PVLA) is preparing for a potential commercial launch of QTORIN rapamycin while advancing additional rare skin and vascular anomaly programs, Chief Financial Officer Matt... 
Via MarketBeat
News headline image
Palvella Therapeutics to Present Phase 3 SELVA and Phase 2 TOIVA Results, Along With New Pediatric Analyses, at 2026 PeDRA Annual Conference
From Palvella Therapeutics Inc.
Via GlobeNewswire
News headline image
Palvella Therapeutics to Participate in the Chardan 10th Annual Healthcare Conference
From Palvella Therapeutics Inc.
Via GlobeNewswire
News headline image
Palvella Therapeutics Announces Three Poster Presentations Highlighting New Data in Microcystic Lymphatic Malformations and DSAP at Fall Clinical Dermatology 2026
From Palvella Therapeutics Inc.
Via GlobeNewswire
News headline image
U.S. Food and Drug Administration Awards Additional Funding for QTORIN™ Rapamycin for the Treatment of Microcystic Lymphatic Malformations
From Palvella Therapeutics Inc.
Via GlobeNewswire
News headline image
Palvella Therapeutics Appoints James R. Treat, M.D., Nationally Recognized Pediatric Dermatologist as Chief Medical Officer
From Palvella Therapeutics Inc.
Via GlobeNewswire
News headline image
Palvella Therapeutics to Participate in Upcoming Healthcare Investor Conferences
From Palvella Therapeutics Inc.
Via GlobeNewswire
News headline image
Palvella Therapeutics Completes Rolling Submission of New Drug Application to FDA for QTORIN™ Rapamycin for the Treatment of Microcystic Lymphatic Malformations
From Palvella Therapeutics Inc.
Via GlobeNewswire
News headline image
Palvella Therapeutics Eyes 2027 QTORIN Approval as Rare-Disease Pipeline Expands ↗
Palvella Therapeutics (NASDAQ:PVLA) is advancing topical therapies for serious rare skin diseases and vascular malformations that lack FDA-approved treatments, with its lead candidate, QTORIN... 
Via MarketBeat
News headline image
Palvella (PVLA) Q2 2026 Earnings Call Transcript ↗
Rare skin disease biotech reports $250.6M cash, plans 2027 FDA approval for lead therapy. 
Via The Motley Fool
Topics Earnings
News headline image
Palvella Therapeutics to Participate in the Canaccord Genuity 46th Annual Growth Conference
From Palvella Therapeutics Inc.
Via GlobeNewswire
News headline image
Palvella Therapeutics Q2 Earnings Call Highlights ↗
Palvella Therapeutics (NASDAQ:PVLA) said it remains on track to complete its new drug application submission for QTORIN rapamycin in microcystic lymphatic malformations, or mLM, during the second half... 
Via MarketBeat
Topics Earnings
News headline image
Full Transcript: Palvella Therapeutics Q2 2026 Earnings Call ↗
Palvella Therapeutics (NASDAQ:PVLA) held its second-quarter earnings conference call on Tuesday. Below is the complete transcript from the call. This transcript is brought to you by Benzinga APIs. For... 
Via Benzinga
News headline image
Palvella Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update
From Palvella Therapeutics Inc.
Via GlobeNewswire
News headline image
Palvella Therapeutics Chief Scientific Officer Jeff Martini, Ph.D. Selected to Present at Upcoming FDA Public Workshop on Drug Repurposing
From Palvella Therapeutics Inc.
Via GlobeNewswire
News headline image
Palvella Therapeutics to Host Second Quarter 2026 Financial Results and Corporate Update Conference Call on August 4, 2026
From Palvella Therapeutics Inc.
Via GlobeNewswire
News headline image
Palvella Therapeutics Appoints Accomplished Rare Disease Biotech Executive and Commercial Leader Matt Pauls, J.D., M.B.A., to Board of Directors
From Palvella Therapeutics Inc.
Via GlobeNewswire
News headline image
Palvella Therapeutics Submits First Module of Rolling New Drug Application to FDA for QTORIN™ Rapamycin for the Treatment of Microcystic Lymphatic Malformations
From Palvella Therapeutics Inc.
Via GlobeNewswire
News headline image
What to Know About This $476,000 Palvella Therapeutics Insider Sale After a 620% Stock Rally ↗
Focused on rare skin disease therapies, this clinical-stage biotech just reported a notable insider sale amid a year of sharp stock gains. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
FDA Grants Rolling Review of Palvella’s QTORIN™ Rapamycin NDA for Microcystic Lymphatic Malformations
From Palvella Therapeutics Inc.
Via GlobeNewswire
News headline image
Palvella Therapeutics Announces Completion of FDA Pre-NDA Meeting for QTORIN™ Rapamycin in Microcystic Lymphatic Malformations
From Palvella Therapeutics Inc.
Via GlobeNewswire
News headline image
Palvella Therapeutics to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference 2026
From Palvella Therapeutics Inc.
Via GlobeNewswire
News headline image
Palvella Therapeutics Strengthens QTORIN™ Pitavastatin Intellectual Property with Yale-Licensed U.S. Patent Providing Protection into 2043
From Palvella Therapeutics Inc.
Via GlobeNewswire
< Previous 1 2 3 4 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Starting at /week.